# Lisata Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Lisata Therapeutics, Inc). ## Overview Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors. The company is built around its CendR Platform and is currently pre-commercial, with development activity centered on oncology and other major diseases. ## Products & services • Certepetide (formerly LSTA1 / CEND-1) • CendR Platform® tumor-penetration technology • Solid tumor oncology development programs • Research license and collaboration arrangements • Clinical development and regulatory advancement services - **Clinical-stage therapeutic candidate** (70%) — Development of certepetide and related oncology programs intended to improve treatment penetration in solid tumors. - **Platform technology** (20%) — The CendR Platform® is the core enabling technology used to activate active transport into tumors. - **Research licensing and collaborations** (10%) — Upfront fees and partner-funded research arrangements tied to preclinical and clinical development. - Certepetide, an investigational solid-tumor penetration therapy - CendR Platform® active transport mechanism - Oncology drug-delivery enhancement for co-administered therapies - Clinical-stage development programs and proof-of-concept trials - Research licensing and collaboration agreements ## Customers Lisata does not yet sell approved medicines, so its near-term counterparties are research partners, licensors, and clinical collaborators rather than end patients. If approved, its commercial customers would be physicians, hospitals, cancer centers, and payors that decide whether certepetide-based regimens are adopted and reimbursed. - **Research and licensing partners** (primary) — Companies or institutions that pay upfront fees or collaborate on development using the CendR Platform. - **Clinical investigators and CROs** (primary) — Trial sites and research organizations that execute studies needed to advance certepetide. - **Oncology providers** (secondary) — Physicians, hospitals, and cancer centers that would prescribe or administer the therapy if approved. - **Third-party payors** (secondary) — Insurers and government programs that would influence access, pricing, and reimbursement. - Pharma and biotech partners licensing the CendR Platform - Clinical research collaborators supporting trials - Oncologists and cancer centers if products are approved - Hospitals and treatment networks evaluating adoption - Government and private payors that determine reimbursement ## Geography Lisata is headquartered in the United States but conducts operations through an Australian subsidiary, which creates a meaningful international operating footprint. Its development and commercialization plans are global in nature, but the company currently has no sales infrastructure and remains dependent on clinical, regulatory, and partnership activity rather than product revenue. - Headquartered in Basking Ridge, New Jersey, United States - Operates through an Australian subsidiary for part of its business - Clinical and regulatory activity may span multiple jurisdictions - No commercial sales footprint yet, so geography is development-driven - International operations add tax, compliance, and execution risk ## Strategy The company’s strategy is to advance certepetide through clinical development, secure regulatory approvals, and build evidence that the platform improves delivery of existing cancer therapies. Near term, it is also focused on preserving liquidity through partnerships, grants, and other non-dilutive funding while it evaluates strategic transactions, including the announced acquisition by Kuva Labs. - **Clinical development of certepetide** (short-term) — Clinical data are needed to validate the platform and support regulatory filings. - **Capital preservation and financing** (short-term) — The company has operating losses and needs external funding to continue development. - **Strategic partnering and commercialization optionality** (medium-term) — Partnerships can provide funding, validation, and a route to market without building a full sales force. - Advance certepetide through clinical proof-of-concept studies - Demonstrate improved penetration and efficacy in solid tumors - Pursue partnerships and collaborations to fund development - Seek grants and non-dilutive capital to extend runway - Prepare for commercialization or out-licensing if approved - Manage strategic transaction process with Kuva Labs ## Risks Lisata faces the classic risks of a clinical-stage biotech: trial failure, regulatory setbacks, reimbursement uncertainty, and the need to raise capital before any meaningful product revenue exists. Company-specific risks also include dependence on an Australian subsidiary, cybersecurity and contractor execution risk, and uncertainty around the proposed Kuva acquisition. - **Clinical development failure** [critical] — Certepetide is investigational, so negative trial data would impair the platform and future value. - **Regulatory approval risk** [high] — The company has no approved products, and approval is required before commercialization. - **Liquidity and going-concern risk** [critical] — Operating losses and limited revenue mean continued funding is required to sustain operations. - **Commercial reimbursement risk** [high] — Even if approved, uptake depends on coverage and pricing by payors and health systems. - **International subsidiary and tax risk** [medium] — Operations through Australia could be affected by tax-credit eligibility or local operating changes. - **Transaction execution risk** [medium] — The proposed Kuva acquisition is subject to closing conditions and could fail or be delayed. - Clinical trials may fail to show efficacy or safety benefits - Regulatory approval is uncertain across jurisdictions - The company may not secure funding on acceptable terms - Commercial adoption depends on physician and payor acceptance - International operations create tax and compliance exposure - The proposed Kuva acquisition may not close on schedule ## Accounting Revenue is minimal and appears to come from upfront license fees, so timing of collaboration and license recognition can materially affect quarter-to-quarter results. The company also relies heavily on stock-based compensation, clinical trial accruals, and estimates around going-concern and liquidity disclosures, all of which can meaningfully affect reported losses and balance-sheet presentation. - **Revenue recognition for license fees** — Can cause uneven quarterly revenue - **Clinical trial accruals** — Affects operating loss and comparability - **Stock-based compensation** — Inflates reported operating costs without cash outflow - **Going-concern assessment** — Signals financing dependence and balance-sheet risk - Upfront license fees can create lumpy revenue recognition - Clinical trial and CRO accruals depend on management estimates - Stock-based compensation has been a significant expense driver - Going-concern assessment affects investor interpretation of solvency - Australian tax credits and subsidiary accounting may affect results --- *Last updated: 2026-09-24T11:14:39.427109+00:00*